Recursion Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported total revenue of $2,549,000 against $186,000 a year ago. Loss from operations was $40,929,000 against $18,217,000 a year ago. Net loss and comprehensive loss was $43,401,000 or $0.31 basic and diluted per share against $18,493,000 or $0.88 basic and diluted per share a year ago. For the six months, the company reported total revenue of $5,111,000 against $246,000 a year ago. Loss from operations was $71,413,000 against $36,560,000 a year ago. Net loss and comprehensive loss was $74,118,000 or $0.91 basic and diluted per share against $37,367,000 or $1.73 basic and diluted per share a year ago.